<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00057850</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02523</org_study_id>
    <secondary_id>UPCC-04302</secondary_id>
    <secondary_id>NCI-5787</secondary_id>
    <secondary_id>CDR0000276716</secondary_id>
    <nct_id>NCT00057850</nct_id>
  </id_info>
  <brief_title>BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer</brief_title>
  <official_title>Phase I/II Trial of the Epothilone B Analogue BMS 247550 (NSC 710428)/Cisplatin in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I/II trial to study the effectiveness of combining BMS-247550 with cisplatin in&#xD;
      treating patients who have metastatic or recurrent head and neck cancer. Drugs used in&#xD;
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Combining more than one drug may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the recommended phase II dose of BMS-247550 when administered with cisplatin in&#xD;
      patients with metastatic or recurrent squamous cell carcinoma of the head and neck. (Phase I)&#xD;
      II. Determine the toxic effects of this regimen in these patients. III. Determine the&#xD;
      response rate, time to progression, and survival of patients treated with this regimen.&#xD;
      (Phase II) IV. Determine the pharmacokinetics of this regimen in these patients. V. Correlate&#xD;
      selected markers from peripheral blood mononuclear cells and tumor samples with toxicity and&#xD;
      response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of BMS-247550.&#xD;
&#xD;
      Phase I: Patients receive BMS-247550 IV over 3 hours and cisplatin IV over 30-60 minutes on&#xD;
      day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose at which at least 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional&#xD;
      patients receive treatment as above at the recommended phase II dose of BMS-247550.&#xD;
&#xD;
      Phase II: Patients receive treatment as in Phase I at the recommended phase II dose of&#xD;
      BMS-247550.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: Patients receive BMS-247550 IV over 3 hours and cisplatin IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment as above at the recommended phase II dose of BMS-247550.&#xD;
Phase II: Patients receive treatment as in Phase I at the recommended phase II dose of BMS-247550.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma of the head and neck considered&#xD;
             incurable by surgery or radiotherapy&#xD;
&#xD;
               -  No nasopharyngeal disease as primary site&#xD;
&#xD;
          -  Extensive, local-regional or distant metastatic disease&#xD;
&#xD;
               -  Newly diagnosed OR&#xD;
&#xD;
               -  Recurrent disease after initial treatment with surgery or radiotherapy (including&#xD;
                  neoadjuvant chemotherapy or concurrent chemoradiotherapy)&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  If only site of measurable disease is in a previously irradiated area, disease&#xD;
                  progression after radiotherapy must be documented&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Transaminases no greater than 2 times upper limit of normal (ULN) (5 times ULN if&#xD;
             liver involvement)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No evidence of active infection&#xD;
&#xD;
          -  No other malignancy within the past 2 years except curatively treated stage 0 or I&#xD;
             cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for recurrent disease&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diane M. Hershock, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2003</verification_date>
  <study_first_submitted>April 7, 2003</study_first_submitted>
  <study_first_submitted_qc>April 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2003</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>salivary gland squamous cell carcinoma</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

